+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05886920

Phase 12 Study Evaluating Oral D3S-002 Alone or with D3S-001 in Adults with Advanced Solid Tumors Having MAPK Pathway Mutations

Led by D3 Bio (Wuxi) Co., Ltd · Updated on 2026-09-29

67

Participants Needed

18

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, tolerability, how the body processes the drug, and the best dose for a new oral medicine called D3S-002 in adults with advanced solid tumors that have specific mutations in the MAPK pathway. This is a first-in-human trial involving adults with cancers that have progressed despite prior treatments. The study aims to find the recommended dose for future studies and to evaluate the drug as a single treatment or combined with another drug, D3S-001. The study has two main parts Part 1 involves gradually increasing doses of D3S-002 given orally to find a safe dose, while Part 2 includes dose escalation and expansion phases where D3S-002 is given with D3S-001, both administered by mouth. Treatment cycles last 21 days, and participants receive the study drugs daily during these cycles. The study is open-label, meaning both doctors and participants know which treatment is given. Participants will be closely monitored for side effects, how the drugs behave in the body, and tumor response using established criteria. Safety is tracked from the first dose until 30 days after stopping treatment, and dosing effects are followed for up to 24 months. Genetic testing on tumor tissue or blood samples is part of the study, along with regular assessments of organ function, performance status, and disease progression. The study continues until disease progression or other reasons to stop treatment.

CONDITIONS

Brief Title

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Research Team

M

Medical Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here